Adenosine reverses a preestablished CCl4-induced micronodular cirrhosis through enhancing collagenolytic activity and stimulating hepatocyte cell proliferation in rats.
Cirrhosis is one of the most common causes of mortality worldwide, because hepatic dysfunction constitutes a potentially lethal condition. Having demonstrated the hepatoprotective effect of adenosine against CCl(4)-induced cirrhosis, the present study was aimed at assessing adenosine's effect on an already-established micronodular cirrhosis. Chronic administration of CCl(4) (10 weeks) induced a cirrhotic state, characterized by increased liver fibronectin and collagen types I and III content, enhanced expression of alpha-1 (I) collagen mRNA, portal hypertension, and liver dysfunction. After CCl(4) discontinuation (5 weeks), increased persitance of alpha-1 (I) collagen mRNA expression and deposition, enhanced proline incorporation into collagen and prolyl hydroxylase activity evidenced active fibrogenesis. Several weeks after CCl(4) withdrawal, deposited collagen showed an enhanced type I/III ratio, which was associated with deficient collagenolytic activity in cirrhotic livers. Liver expression of some metalloproteinases (MMPs) and of tissue inhibitors of MMPs (TIMPs) also indicated decreased collagen breakdown in cirrhotic livers. Parameters indicative of oxidative stress (mainly protein oxidation) were persistently augmented. These events were coincident with diminished regenerative capacity of the cirrhotic liver. Intraperitoneal adenosine administration to CCl(4)-induced cirrhotic rats blocked active fibrogenesis and increased the collagen degradation (most probably by decreasing liver TIMPs levels), normalizing collagen-type ratios. In addition, the nucleoside promoted an effective hepatocyte's proliferation in the cirrhotic liver and accelerated normalization of parameters indicative of liver function and oxidative stress. Thus, adenosine readily reversed an experimental cirrhosis through stimulating liver collagenolytic and proliferative capacities, as well as by accelerating functional recovery.
Hernández-Muñoz
R
R
Departamento de Biología Celular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México.
Díaz-Muñoz
M
M
Suárez-Cuenca
J A
JA
Trejo-Solís
C
C
López
V
V
Sánchez-Sevilla
L
L
Yáñez
L
L
De Sánchez
V C
VC
D000241:Adenosine / Q000627:therapeutic use*; D000818:Animals; D002251:Carbon Tetrachloride / Q000633:toxicity*; D002455:Cell Division / Q000187:drug effects; D003094:Collagen / Q000032:analysis / Q000378:metabolism*; D004247:DNA / Q000096:biosynthesis; D005353:Fibronectins / Q000032:analysis; D022781:Hepatocytes / Q000187:drug effects* / Q000378:metabolism; D006975:Hypertension, Portal / Q000517:prevention & control; D008099:Liver / Q000737:chemistry / Q000378:metabolism; D008106:Liver Cirrhosis, Experimental / Q000188:drug therapy* / Q000378:metabolism; D008115:Liver Regeneration / Q000187:drug effects; D008297:Male; D018384:Oxidative Stress; D051381:Rats; D017208:Rats, Wistar
D005353:Fibronectins; D003094:Collagen; D004247:DNA; D002251:Carbon Tetrachloride; D000241:Adenosine